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Phosphorylated osteopontin peptides suppress crystallization stones is a complex process involving multiple factors.
by inhibiting the growth of calcium oxalate crystals. Although the saturation product for CaOx is frequently
Background. Osteopontin isolated from human urine [uro- exceeded in normal urine, most humans do not formpontin (uOPN)] is a potent inhibitor of calcium oxalate (CaOx)
stones. It has been presumed that inhibitors of CaOxmonohydrate (COM) crystallization. However, specific struc-
crystallization have protective effects, although their pre-tural features responsible for its effects on CaOx crystallization
were not previously known. The present studies were designed cise role has not been defined. The majority of the inhibi-
to define molecular features responsible for interactions of tion of crystal growth observed in assays of normal urine
uOPN with COM crystals and the inhibition of crystallization.
is due to the presence of protein macromolecules [2, 3].Methods. Peptides and phosphopeptides with sequences
We isolated a urinary protein inhibitor of CaOx crystalcorresponding to potential crystal binding domains within the
protein sequence of osteopontin were synthesized. Then the growth by immunoaffinity chromatography. The N-termi-
effects of these peptides on COM crystal growth and crystal nal amino acid sequence of this urinary protein is identi-
aggregation were investigated and their secondary structures cal to that of human osteopontin (OPN), a phosphory-analyzed.
lated matrix protein previously isolated from bone [4, 5].Results. Growth of COM crystals was inhibited by 50%
Its name connotes the potential bridging role in facilitat-at 1000 nmol/L concentrations by the two unmodified peptides
with the closest clustering of aspartic acid residues. Growth ing interactions between cells and mineralized matrix
was not inhibited by the other two unmodified peptides, with proposed on the basis of having a functionally active
aspartic residues more evenly distributed within their se-
cell-binding Arg-Gly-Asp-Ser (RGDS) sequence and se-quences. Phosphorylation markedly increased inhibition of
quence domains rich in dicarboxylic acids [6]. To denoteCOM crystal growth, so that each of the four phosphorylated
peptides inhibited growth by at least 50% at concentrations of its urinary origin, we refer to urinary OPN by its contrac-
200 nmol/L. Phosphorylation of these peptides did not cause tion, uropontin (uOPN). This protein is a very potent
changes in secondary structure that would favor interaction inhibitor of CaOx crystallization in vitro. uOPN inhibitswith COM crystal surfaces.
the growth of CaOx monohydrate (COM) crystals byConclusions. These studies of synthetic peptides identify
50% at 16  2 nmol/L and inhibits the aggregation ofmolecular features within the osteopontin molecule that con-
tribute to the inhibition of one aspect of COM crystallization. COM crystals by 50% at 28  4 nmol/L [7]. Thus, levels
The inhibition of crystal growth induced by phosphorylation of uOPN present in normal human urine are inhibitory
appears to result from altered local patterns of charge density,
for both of these aspects of COM crystallization [7–9].since conformational changes favoring interaction with crystals
The primary structure of human OPN contains anwere not caused by phosphorylation.
abundance of acidic amino acids with 48 aspartic acid and
27 glutamic acid residues in its 298 amino acid peptide
sequence. Many of the aspartic acid residues are clus-Urinary tract stone disease is a common chronic disor-
tered together in the N-terminal half of the protein. Theder in humans, with the majority of calculi being calcium
human OPN sequence also contains 42 serines and 14oxalate (CaOx) stones [1]. The formation of urinary
threonines. Many of these highly conserved residues are
in suitable positions for phosphorylation. They haveKey words: crystal growth, polyaspartic acid, stone disease, nephrolithi-
asis, uropontin. been shown to be phosphorylated in vivo by a combina-
tion of sequence analysis of S-ethylcysteine-derivitized
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Fig. 1. Sequences of amino acids from 62 to 116 of the OPN sequence in the four pairs of peptides used for the crystallization studies shown in
Figures 2 and 3. The molecular weights of the four unmodified peptides ranged from 1591 to 3031, and the molecular weights of the four
phosphorylated peptides ranged from 1828 to 3268. Three pairs of the peptides contain 3 serine (S) or threonine (T) phosphorylation sites, while
peptide 99 to 115 has 5 serines. Peptide 62 to 85 has a single casein kinase phosphorylation site. Peptide 93 to 106 has three and peptide 99 to
115 has five of these sites. The fraction of aspartic (D) or glutamic (E) acids in the four peptides were comparable with 54% of the amino acids
in the first two peptides and 47 or 57% of the amino acids in the two later peptides being either D or E.
creased inhibition of hydroxyapatite crystal growth was METHODS
seen after dephosphorylation of OPN [13, 14]. These Peptides were synthesized on Milligen 9050 and Rai-
latter observations suggest that phosphorylation of full nin PS3 automatic synthesizers using 9-fluorenylmeth-
OPN molecules might also have a functional role in CaOx oxycarbonyl amino acids according to standard proce-
crystallization. dures [18]. Individual phosphorylated serine residues
In addition to the obvious implications for clinical were incorporated as Fmoc-Ser (PO3HBzl)-OH [19],
stone disease, studies of the process of crystallization purchased from Novabiochem, Ltd. (Newton, MA, USA).
leading to stone formation in the urinary tract and the Global phosphorylation of all potential serine and threo-
elements contained in urine provide a model system for nine residues in the peptides was achieved with polyp-
biologic control of mineralization in other body fluids. hosphoric acid after cleavage [20]. Peptides and phos-
Although uOPN inhibits several aspects of COM crystal- phopeptides were detached from the solid support with
lization [7], specific structural features responsible for trifluoroacetic acid (TFA) and were purified by reversed-
its effects on CaOx crystallization were not previously phase high-performance liquid chromatography (RP-
known. To define molecular features causing inhibition HPLC) using an aqueous acetonitrile gradient elution
of crystallization through interactions with COM crys- system containing 0.1% TFA as an ion-pairing reagent.
tals, we synthesized peptides and phosphopeptides with In the case of global phosphorylation, the earliest eluting
sequences corresponding to those in the human OPN HPLC fractions were collected (representing the highest
protein sequence. level of phosphate incorporation). The integrity of the
Aspartic acid-rich proteins are closely associated with peptides and phosphopeptides was verified by matrix-
mineralization in a broad range of organisms and tissues assisted laser ionization/desorption mass spectroscopy in
[4], and large polyaspartic acid polymers have inhibited the Protein Microchemistry Laboratory of the Wistar
CaOx crystal growth [15, 16]. Accordingly, we selected Institute (Philadelphia, PA, USA).
from the full OPN sequence, a 54 amino acid segment Inhibition of CaOx crystal growth was measured using
with an abundance of highly conserved aspartic acid resi- a seeded, solution-depletion assay. Loss of absorbance
dues for the present investigations (Fig. 1). Within this at 214 nm was monitored continuously after addition of
region, the 10 consecutive aspartic acids in the mouse COM seed crystals and reflects consumption of oxalate
sequence are fully conserved in at least seven of the into the COM seed crystals [21]. After calculation of the
positions in each of five other mammalian species and initial rate, inhibition expressed as a ratio of rate with
the chicken; more than one nonconservative substitution protein to the control rate. Inhibition of CaOx crystal
is present in only the cow and chicken [17]. This region aggregation was determined using a particle size assay
of OPN also contains highly conserved serines and a [22]. Spontaneous sedimentation of particles from a well-
threonine in positions that have been shown to be phos- equilibrated COM crystal slurry was measured by moni-
phorylated in vivo [10]. Thus, we could evaluate the toring absorbance at 620 nm for 300 seconds after aggre-
relative contributions of aspartic acid residues and phos- gation was initiated. The slope of absorbance reflects
phorylation to the functional activities of these OPN free-fall velocity, which is proportional to particle size
peptides. The effects of these peptides on CaOx crystal and was calculated as previously described [22].
growth and crystal aggregation were determined. The Circular dichroism (CD) spectra were taken on a Jasco
secondary structure of these peptides was also analyzed J720 instrument at room temperature in a 0.2 mm path-
length cell. Double-distilled water and spectroscopy-to evaluate potential contributions of conformational
changes induced by phosphorylation to functional activi- grade trifluoroethanol (TFE) were used as solvents. The
peptide concentration was about 0.5 mg/mL, determinedties. Our studies demonstrate a major contribution of
phosphorylation to the inhibition of CaOx crystal growth each time by quantitative RP-HPLC [23]. Since second-
ary structures of peptides (especially phosphopeptides)by these small OPN peptides.
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provided by the current computer-assisted curve-analyz-
ing algorithms show a high error rate, the CD spectra
evaluations were based on comparisons with known pep-
tide conformations [24, 25].
RESULTS
We studied the effects on growth and aggregation of
COM crystals of the series of peptides with the sequences
shown in Figure 1 and their phosphorylated counter-
parts. This region contains an abundance of aspartic acid
residues as well as serines and a threonine in positions
suitable for phosphorylation. Thus, we were able to eval-
uate the contribution of aspartic acids and of phosphory-
lation to the function of these peptides.
As shown in Figure 2A, growth of COM crystals was
inhibited by 50% at 1000 nmol/L of the earlier two
unmodified peptides, but was not inhibited by the other
two unmodified peptides (Fig. 2B), with aspartic residues
more evenly distributed within their sequences. Phos-
phorylation markedly increased inhibition of COM crys-
tal growth so that each of the four phosphorylated pep-
tides inhibited growth by at least 50% at concentrations
of 200 nmol/L.
However, in contrast to the potent inhibition of COM
crystal growth by these phosphorylated peptides, they
did not inhibit aggregation of COM crystals (Fig. 3).
None of the concentrations as high as 10,000 nmol/L of
any of the four unmodified peptides or their phosphory-
lated counterparts reduced the aggregation of COM crys-
tals by 50%.
The secondary structure of these OPN peptides was
analyzed by CD spectroscopy to determine if the effects
on functional activities of OPN peptides were the conse-
quence of changes in peptide conformation induced by
phosphorylation. We had previously studied synthetic
peptides corresponding to sequences of tau, a neural
protein that accumulates in Alzheimer’s disease. Phos-
phorylation of tau peptides resulted in major conforma- Fig. 2. (A and B) Inhibition of CaOx crystal growth by synthetic
peptides (open symbols) and phosphorylated synthetic peptides (closedtional effects that included reversible -pleated sheet
symbols) corresponding to amino acids in the portion of the osteopon-formation or stabilization of turn structures [26, 27]. Ef-
tin sequence shown in Figure 1 as follows: 62 to 85 (triangles) and 66
fects induced by divalent cations on the conformation to 91 (diamonds), 93 to 106 (circles) and 99 to 115 (squares).
of these neural peptides were profoundly influenced by
phosphorylation [26, 28, 29]. Our studies of the CD spec-
tra of the full OPN molecule showed that exposure to
in water. Peptide 93-106 was the only one having spectracalcium ions increased the fraction of -pleated sheet
suggestive of -pleated sheets in TFE. However, thestructure [30]. However, the present studies of effects of
structure of phosphorylated peptide 93-106 in water wasphosphorylation on the structure of OPN peptides did
completely unordered. In contrast to major conforma-not show comparable changes when analyzed using iden-
tional changes induced in phosphorylated tau peptidestical conditions. Notably, phosphorylation generally re-
[26, 28, 29], the addition of Ca2, Mg2, or Al3 to thesulted in a decrease or loss of ordered structure of the
OPN phosphopeptides did not generate -pleated sheetunmodified OPN peptides. Peptides of this length gener-
formation or other new secondary structure.ally assume the conformation of a single conformational
Since the four phosphorylated peptides from the OPNelement; this primarily consisted of  turns in the spectra
of these OPN peptides in TFE with less ordered structure sequence inhibited the growth, but not the aggregation
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Fig. 4. Inhibition of CaOx crystal growth () and aggregation ( )
by polyaspartic acid (molecular weight 11,000).
Fig. 3. Inhibition of CaOx crystal aggregation by the four synthetic
peptides () and the four phosphorylated peptides () shown in Figure
2 (mean  SD).
tures responsible for functional activities of uropontin
are at least partially separable; the phosphorylated OPN
peptides were potent inhibitors of COM crystal growth,of COM crystals, effects of a model polypeptide, poly-
but not of COM crystal aggregation.aspartic acid (molecular weight of 11,000 D), on the
Potent inhibition of crystal growth appears to requiregrowth and the aggregation of COM crystals were also
a protein structure that binds to crystals on the basis ofcompared. This analysis (Fig. 4) showed inhibition of
specific patterns of charge density. Although an abun-crystal growth by molar concentrations of polyaspartic
dance of carboxylic acid residues in AARPs suggests theacid that were slightly higher than inhibitory levels of
potential for interaction with crystal surfaces, conforma-full uropontin molecules. By contrast, inhibition of COM
tions adopted by these proteins may also underlie specificcrystal aggregation by 50% required mol/L (that is,
interactions that lead to modulation of crystal growth.1000 times higher) levels of polyaspartic acid. The ef-
For example, the aspartic acid-rich proteins extracted withfect of polyaspartic acid on COM crystal aggregation is
ethylenediaminetetraacetic acid (EDTA) from molluskquite weak when compared with 50% inhibition by 28 
shells adopted a -sheet conformation upon exposure to4 nmol/L of uropontin using identical experimental con-
calcium [34]. Exposure of immunopurified rat OPN toditions [7].
calcium ions also significantly increased the -sheet
structure in CD spectra [30]. However, in contrast to
DISCUSSION findings in our studies of full OPN molecules and neural
peptides [26–29], conformational changes of OPN pep-Aspartic acid-rich proteins (AARPs) are closely asso-
tides favoring interactions with crystals did not resultciated with mineralization in a broad range of organisms
from phosphorylation and/or exposure to divalent cations.and tissues [4]. Furthermore, a series of elegant in vitro
Thus, by default, the contribution of phosphorylation tostudies have demonstrated tissue-specific patterns of
functional activity of these peptides appears to resultmodulation of crystal growth by AARPs from other min-
from changes in localized patterns of charge density.eralizing tissues [31–33]. However, contributions of indi-
Inhibition of CaOx crystal growth by homopolymersvidual domains within an AARP to the modulation of
of aspartic acid [15, 16] suggested that the close proximityCaOx crystallization were not previously known. The
of a series of aspartic acid residues within OPN mightpresent investigation showed that phosphorylation mark-
also cause growth inhibition. It should be noted thatedly increased the inhibition of COM crystal growth by
chains of aspartic acid residues in these model polymerseach of the four OPN peptides analyzed. These findings
were at least five- to tenfold longer than the longestshow that the full protein is not required for functional
series of aspartic acids in native OPN molecules. In theactivity, since these small domains of the OPN primary
present studies, a minor role for close proximity of aspar-sequence were able to independently inhibit COM crys-
tal growth. Our studies also showed that molecular fea- tic acids within the OPN sequence was suggested by
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inhibition of crystal growth by unmodified peptides 62-85 OPN is an important determinant of inhibitory activity.
Thus, analysis of the extent of phosphorylation of uOPNand 66-91 (Fig. 2A), but not by the later unmodified pep-
tides (Fig. 2B). However, micromolar levels of unmodified will contribute to the molecular definition of the func-
tional abnormality in such patients with decreased inhibi-peptides 62-85 and 66-91 were required to achieve inhibi-
tion comparable to 20 nanomolar levels of full uOPN tion of crystallization by their uOPN.
molecules in identical experimental conditions [7] or40
nanomolar levels of polyaspartic acid (Fig. 4). ACKNOWLEDGMENT
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